Can ashwagandha boost chemo in ovarian cancer? new trial aims to find out
NCT ID NCT05610735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) for people whose ovarian cancer has returned. The goal is to find a safe dose and see if the combination helps shrink tumors or slow cancer growth. About 72 participants with recurrent ovarian cancer will take part in two phases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UofL Health Brown Cancer Center
RECRUITINGLouisville, Kentucky, 40202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to outsmart recurrent ovarian cancer
- Could your own immune cells fight ovarian cancer? tiny trial aims to find out
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- New drug duo aims to stall ovarian Cancer's return
- New hope for hard-to-treat ovarian cancer: combo therapy enters human trial